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Introduction  
The 80kD glycoprotein transferrin (TF) and its 
related receptor (TFR1) play a major role in the 
recruitment by cancer cells of factors for their 
multiplication, adhesion, invasion and metastat-
ic potential. Though primarily designed to bind 
iron and then be internalised into cells with its 
receptor, TF can also bind most transition metals 
such as Co, Cr, Mn, Zr, Ni, Cu, V, In & Ga. Under 
certain conditions TF binds Ti (IV) even more 
tightly than it does Fe and that this occurs at the 
N-lobe (as distinct from C) of apoTF. Further, 
under physiological conditions the species 
Fe(C)Ti(N)-TF may provide the route for Ti entry 
into cells via TFR1 (1). Thus, the radiometal PET 
reporter isotope 45Ti with an ‘intermediate’ 
(~hrs) half-life suited to tracking cell-focused 
biological mechanisms is an attractive option for 
elucidating cellular mechanisms involving TF 
binding and internalisation, at least in (preclini-
cal) animal models.   
    45Ti (T½ = 3.08 hr; β
+ branching ratio = 85 %; 
mean β+ energy = 439keV, no significant dose-
conferring non-511keV γ-emissions) was pro-
duced using the reaction 45Sc(p,n)45Ti by irradiat-
ing (monoisotopic) scandium discs with an ener-
gy-degraded  proton beam produced by an 
18MeV isochronous medical cyclotron. Separa-
tion and purification was achieved with an hy-
droxylamine hydrochloride functionalised resin. 
Comparative microPET imaging was performed 
in an immunodeficient mouse model, measuring 
biodistributions of the radiolabels 45Ti-oxalate 
and 45Ti-human-TF (45Ti-h-TF), out to 6hr post-
injection. 
 
Materials and Methods 
High purity 15mm diameter scandium disc foils 
(99.5%, Goodfellow, UK) each thickness 0.100 ± 
0.005 mm (55 mg) were loaded into an in-house 
constructed solid-targetry system mounted on a 
300mm external beam line utilising helium-gas 
and chilled water to cool the target body (2). 
The proton beam was degraded to 11.7 MeV 
using a graphite disc integrated into the graphite 
collimator. This energy abolishes the competing 
‘contaminant’ reactions 45Sc(p,n+p)44Sc and 
45Sc(p,2n)44Ti. Beam current was measured using 
the well documented 65Cu(p,n)65Zn reaction. 
Calculations showed that the chosen energy is 
close to the optimal primary energy (~12 MeV) 
for maximising the (thin-target) yield from a 
0.100 mm thick target.  
    For separation of Ti from the Sc target two 
methods were examined; (i) ion exchange col-
umn separation using 2000 mg AG 50W-X8 resin 
conditioned with 10mL 9M HCl. Disc is dissolved 
in 1 mL of 9M HCl, which at completion of reac-
tion is pipetted into column. Successive 1 mL 
volumes of 9M HCl are added, and subsequent 
elutions collected. (ii) Following Gagnon et al., 
(3) a method employing hydroxylamine hydro-
chloride functionalised resin (’hydroxamate 
method’) was applied, similar to its use in our 
hands for purification and separation of 89Zr (2) 
following its original description for 89Zr by Hol-
land et al., (4). Disc dissolved in 2mL 6M HCl, 
then diluted to 2M. Elute through column to 
waste fraction 1 (w1 – see FIG. 1). Then elute 6 
mL of 2M HCl through column to w2, followed 
by 6 mL of traceSELECT H2O to w3. Finally, elute 
Ti into successive 1 mL product fractions (p1, 2 
etc.) using 5 mL of 1M oxalic acid. This proce-
dure takes approximate 1 hr. 45Ti in elution vials 
was measured using γ-spectroscopy. Sc in the 
same vials was determined later using ICP-MS. 
 
Results 
A typical production run using a beam current of 
40 μA for 60min on a 0.100mm-thick disc pro-
duced an activity of 1.83 GBq. Radionuclidic 
analysis of an irradiated disc using calibrated 
cryo-HPGe γ-spectroscopy revealed T½ = 2.97–
3.19 hr (95% CI) for 45Ti, and with contaminant 
44Sc < 0.19 %, with no other isotopes detected. 
    Despite systematic adjustments to column 
conditions satisfactory chemical separation was 
not achieved using the ion exchange column 
method (i), despite previous reports of its suc-
cess (5). Typical results of separation using the 
successful hydroxamate method (ii) are shown 
on the FIGURE 1. 
    It is seen that significant portion of 45Ti is lost 
in the initial washing steps leading to waste 
collection. N = 4 replicate experiments showed a 
variation (SD) of 10 % of the mean in each elu-
tion fraction. Subsequent ICP-MS of the same 
elutions for (cold) Sc showed approximately 
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80 % by mass appeared in w1 and 20 % in w2, 
with negligible total mass (total fraction 
~1/6000) of Sc in product (p1–4) vials. However, 
the FIG. 1 shows that a total of only 30% of the 
original activity of 45Ti (corrected to EOB) is 
available in the product vials, with the vial of 
highest specific activity (p1) containing 14 %. 
However, using a stack of 2×0.100mm thick Sc 
discs as a target yields isotope of adequate spe-
cific activity without need for concentration, for 
subsequent labelling and small-animal imaging 
purposes. 
 
 
 
FIGURE 1. Profile of 45Ti activity, from γ-spectroscopy, 
expressed as a percentage of total 45Ti EOB activity. 
Elution fractions w1-Ti to w3-Ti were collections from 
the 3 waste stages. Elution fractions p1-Ti to p4-Ti 
were the collected product, each of 1 mL. Elution 
profile for (cold) Sc target mass (ICP-MS) is also 
shown, with very low detection in p-fractions. 
 
In a ‘proof-of-principle’ experiment, two groups 
of healthy Balb/c-nu/nu female adult mice were 
administered with 45Ti radiotracers. The first 
group (N = 3) received approximately 20 MBq IP 
of 45Ti-oxalate buffered to pH = 7.0, and under-
went microPET/CT imaging (Super Argus PET, 
Sedecal, Spain) out to 6hr post-injection, plus 
biodistribution analysis of radioactivity by dis-
section at sacrifice (6hr). The second group (N = 
3) received approximately 20 MBq IP of 45Ti-h-TF 
and were also studied to 6hr post-injection, 
followed by radioactive analysis after dissection 
at sacrifice. Organ and tissue biodistributions of 
the two groups at 6hr were similar but with 45Ti-
oxalate showing slightly greater affinity for 
bone. Biodistribution by dissection results 
broadly confirmed the findings from PET images. 
However, TLC results suggested that similarity of 
radiolabel biodistributions of the two groups 
may be due to contamination of the TF radio-
label with non-conjugated Ti at time of injection. 
An alternative explanation is dechelation in vivo 
of 45Ti from 45Ti-h-TF.  
 
Conclusion  
Despite significant loss of 45Ti to the waste frac-
tions of the separation process (total 53 %, cor-
rected to EOB), 45Ti of acceptable specific activi-
ty and high radionuclidic purity has been pro-
duced from the reaction 45Sc(p,n)45Ti, with 
separation and purification of the product by 
hydroxamate column chemistry, confirming an 
earlier report. Though microPET in vivo imaging 
using 45Ti-based radiolabels was shown to be 
feasible, the similarity in the results for the label 
45Ti-h-TF compared with ‘raw’ 45Ti-oxalate sug-
gests further investigations. These may include a 
direct comparison of in vivo 45Ti-h-TF small-
animal imaging plus post-dissection biodistribu-
tion with the same procedures using 89Zr la-
belled h-apotransferrin (6). 
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